Omission of sentinel lymph node biopsy in early stage luminal breast cancer: impact on adjuvant CDK4/6 inhibitor recommendation and oncological outcomes.

ABSTRACT:

Background

Sentinel lymph node biopsy (SLNB) omission is safe in many patients with small, clinically and imaging node-negative (cN0/iN0), hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC). However, recruitment of the pivotal SOUND/INSEMA trials ended prior to approval of adjuvant cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). Therefore, the impact of SLNB omission on eligibility for CDK4/6i and associated oncological outcomes is unknown.

Methods

Single-center, retrospective study including patients with ≤cT2, cN0/iN0, HR-positive/HER2-negative early BC who underwent breast-conserving surgery and SLNB between 01/2014-12/2024. CDK4/6i eligibility was based on monarchE inclusion criteria and FDA approval (abemaciclib

SUBMITTER: Heidinger M 

PROVIDER: S-EPMC12756710 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature